In high-growth economies the lack of awareness among stakeholders (clinical and non-clinical) is a result of varied priorities, lack of visibility to the problem statement and widespread absence of advocacy. This is compounded with the lack of credible local data.

FSRC is working in these economies on a people centric approach involving relevant stakeholders: clinicians, policy makers, patient groups, advisors and pharma companies. We work in these data limited settings to create awareness for change in disease prevention and management. FSRC has been successful in achieving scientific and inclusive models enriched with innovative approaches to generate credible information ground-up.

  • Supporting the CIS region to take informed decisions in policy to facilitate access
    • In a region undergoing unprecedented economic growth and emerging from an inflexible healthcare system, the ability to prioritize health needs of the population is critical. For the first time in the CIS region we brought together Ministries of Health, patient groups and clinicians to collectively identify processes that would enable better decision making.

      Recommendations arrived at in these pioneering dialogues facilitated by the robust methodologies and frameworks we brought to the table are being actively analysed implementation.

      To work with us:

  • The Silent Plague: Serving the 100,000,000 Africans affected by viral hepatitis
    • Africa bears a quarter of the global burden of disease. We have been working alongside over a 100 local clinical experts, dozens of ministry representatives, patient bodies, local and international disease experts and industry partners to create awareness on a disease that impacts 100 Million Africans. Hepatitis despite overtaking HIV in terms of global death is still a policy stepchild. A situation that we want to alter through continued research, improved awareness and collaboration.

      With our stakeholder meetings in Lagos and Dakar, we have facilitated the creation of a unified Pan-African voice for the battle against hepatitis. We have for the first time enabled a dialogue between the sectors that are impacted by and can impact the disease. The framework of action against hepatitis formulated jointly with these representatives is currently serving as a guiding document to bring about an actionable roadmap for hepatitis prevention and management.

      We are constantly on the lookout for partners who can work with us towards realization of a hepatitis free Africa.

      To work with us:

  • Uncovering the cost burden of ‘The Eleventh Plague’ of Egypt
    • Egypt is burdened with the world’s highest prevalence of hepatitis C. Hepatitis C over time not only impacts the physical wellbeing of the affected individuals, but is a significant financial burden on the individual and the national exchequer. The Ministry has strategic 4 year plans in place to improve the situation. Despite this no study had been carried out to determine the actual economic impact due to hepatitis C on a national level.

      In collaboration with leading Egyptian experts and top-tier institutes, we conducted a retrospective, case-based study to assess the costs involved with management of the complications of hepatitis C infection. The findings clearly outline the need for early management with the right interventions to be able to contain the costs of management of complications. We are currently focusing on leveraging media and scientific channels to disseminate the findings to a wider audience.

      To work with us:

  • Uncovering intervention impact to alleviate chronic sufferers
    • The healthcare ecosystem has conventionally relied on clinical trials to make decisions towards drug usage. However, disease polymorphism, varied genetics and adherence leads to drugs behaving differently in a real world setting. We have worked with industry partners, academic institutes and physicians to setup organized systems to collect uniform unbiased data.

      We have pioneered working in data limited settings by engaging clinicians, academia and industry partners to generate realistic representation to assists informed decision making. Patient registries help in understanding the disease progression, impact of interventions and quality of life of patients over time without impacting the choice of medication unlike clinical trials.

      In Europe, we are currently engaged in unravelling the impact of a medical intervention in a chronic condition. The results of this will assist policy makers and payors to improve drug access programs by basing decisions on scientifically proven, large scale, local data.

      To work with us:

  • Engaging stakeholders in India to formulate recommendations that impact its Billion people
    • On 28th of July, 2013 - World Hepatitis Day, we began our journey towards creating optimal disease awareness and focus for hepatitis by convening an expert panel discussion. To achieve this we brought together a range of clinical and public health experts from the South Zone to arrive at recommendations for prevention and management of hepatitis. The recommendations arrived at were subsequently communicates to the regional and national health authorities and the Prime Minister’s office.

      As an outreach to assess and improve disease knowledge we conducted survey and an awareness lecture for the general population. The findings from the survey clearly outline the lack of adequate awareness and provide a basis for focused activities. We plan to take this initiative to a National level with interested partners to push for policy change towards better management of hepatitis.

      To work with us:

Our Work